Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Bacterium or component thereof or substance produced by said...
Reexamination Certificate
1995-01-25
2004-04-06
Smith, Lynette R. F. (Department: 1645)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Bacterium or component thereof or substance produced by said...
C424S184100, C424S185100, C424S236100, C424S244100, C424S190100, C424S278100, C530S300000, C530S325000, C530S350000
Reexamination Certificate
active
06716432
ABSTRACT:
This invention relates to mutants of the toxin pneumolysin and pneumococcal vaccines based on these mutants.
BACKGROUND OF THE INVENTION
Streptococcus pneumoniae
(pneumococcus) is an important pathogen, causing invasive diseases such as pneumonia, meningitis and bacteremia. Even in regions where effective antibiotic therapy is freely available, the mortality rate from pneumococcal pneumonia can be as high as 19% in hospitalized patients and this increases to 30-40% in patients with bacteremia. These high mortality rates have been reported in the U.S.A. where pneumonia, of which
S. pneumoniae
is the commonest cause, is the fifth ranking cause of death. Indeed, pneumonia is the only infectious disease among the top ten causes of death in that country. In the United States mortality rates for pneumococcal meningitis range from 13-45%. In developing countries, in excess of 3 million children under the age of 5 years die each year from pneumonia, and again
S. pneumoniae
is the commonest causative agent.
S. pneumoniae
also causes less serious, but highly prevalent infections such as otitis media and sinusitis, which have a significant impact on health-care costs in developed countries. Otitis media is especially important in young children; sinusitis affects both children and adults.
In the late 1970's, a vaccine was licensed for the purpose of preventing serious infections, especially bacterial pneumonia and for protecting certain groups, such as splenectomized individuals and young children, who are particularly susceptible to fulminating pneumococcal disease. The vaccine is composed of purified capsular polysaccharides, which are the predominant pneumococcal surface antigens. However, each serotype of
S. pneumoniae
(of which there are 83) has a structurally distinct capsular polysaccharides, and immunization with one serotype confers no protection whatsoever against the vast majority of the others. The vaccine currently licensed in Australia contains polysaccharides purified from the 23 most common serotypes, which account for approximately 90% of pneumococcal infections in this country.
Protection even against those serotypes contained in the vaccine is by no means complete, and there have been several reports of serious, even fatal infections occurring in vaccinated high-risk individuals. The efficacy of the vaccine is poorest in young children, and several studies, including one conducted in Adelaide, have shown that the existing formulation has little or no demonstrable clinical benefit in this group. This apparent failure cm the vaccine appears to be related to the poor immunogenicity of certain pneumococcal polysaccharides in children under 5 years of age. We have shown that the antibody response is particularly poor to the five serotypes which most commonly cause disease in children (types 6, 14, 18, 19 and 23). Indeed, the antibody response to these pneumococcal polysaccharides only approaches adult levels in children over 8 years of age at the time of vaccination.
In view of this, a vaccine, including antigens other than the capsular polysaccharides seems to be required to protect young children from pneumococcal infection. One such antigen could be pneumolysin, a protein toxin produced by all virulent
S. pneumoniae
isolates.
Immunization of mice with this protein has been found to confer a degree of protection from pneumococcal infection. However there is a difficulty in that pneumolysin is toxic to humans. Thus pneumolysin included in a vaccine must therefore be substantially non-toxic. However, the rendering of a pneumolysin non-toxic by most currently employed methods would be likely to alter the basic configuration of the protein so as to be immunogenically distinct from the native or wild-type pneumolysin. An immune response elicited by an altered protein that is immunogenically distinct from the native pneumolysin will have a decreased protective capacity or no protective capacity. Thus the difficulty is to produce an altered pneumolysin that is non-toxic and at the same time sufficiently immunogenically similar to the toxic form to elicit a protective immune response.
An altered pneumolysin with the above characteristics can then be used in a number of ways in a vaccine. Thus the altered pneumolysin may be used by itself to immunize, or alternatively the altered pneumolysin may be conjugated to pneumococcal polysaccharide, or alternatively may be included in a vaccine wherein pneumococcal polysaccharides may be conjugated to another protein and the altered pneumolysin is present in a non-conjugated form only. Alternatively, pneumococcal polysaccharide and pneumolysin may both be used in an unconjugated form.
DESCRIPTION OF INVENTION
In a broad form therefore the invention may be said to reside in an altered pneumolysin being substantially non-toxic and being capable of eliciting an immune response in an animal susceptible to wild-type pneumolysin.
Preferably the altered pneumolysin has reduced complement binding activity as compared to wild-type pneumolysin. Reduction in the complement binding activity results in less inflammation at the site of administering the vaccine.
Preferably the altered pneumolysin has reduced Fc binding activity as compared to wild-type pneumolysin. Reduction in the Fc binding activity results in less inflammation at the site of administering the vaccine.
Preferably the altered pneumolysin is altered by reason of one or more amino acid substitutions relative to wild-type pneumolysin.
The pneumolysin may be altered in that the amino acid present at any one or more than one of residue sites 367, 384, 385, 428, 433 or 435 of wild-type pneumolysin are replaced, removed or blocked.
In a further form the invention could be said to reside in a vaccine including an altered pneumolysin, said altered pneumolysin being nontoxic and being capable of eliciting an immune response in an animal being reactive to wild-type pneumolysin.
Preferably the vaccine comprises capsular polysaccharide material conjugated with the altered pneumolysin.
The capsular material may be derived from any one or more of the
Streptococcus pneumoniae
serotypes 6A, 6B, 14, 18C, 19A, 19F, 23F, 1, 2, 3, 4, 5, 7F, 8, 9N, 9V, 10A, 11A, 12F, 15B, 17F, 20, 22F and 33F.
In this embodiment, serotypes which are commonly associated with disease in children, and to which children generally have a poor immune response, may be specifically targeted (i.e. Danish serotypes 6A, 6B, 14, 18C, 19A, 19F and 23F). Other common serotypes contained in the present 23-valent Merck Sharp and Dohme vaccine (Pneumovax 23) however, could also be used to synthesize conjugates (i.e. types 1, 2, 3, 4, 5, 7F, 8, 9N, 9V, 10A, 11A, 12F, 15B, 17F, 20, 22F and 33F) or indeed any other serotype. Conjugation of any pneumococcal polysaccharides to the protein carrier ensures good T-cell dependent immunogenicity in children, such that protective levels of anti-polysaccharide antibody are produced.
The combination of the altered pneumolysin together with the capsular material will ensure an extra degree of protection, particularly against serotypes of
S. pneumoniae
whose polysaccharides are not incorporated in the existing vaccine formulations.
The vaccine is preferably administered by sub-cutaneous injection, with or without an approved adjuvant, such as alumina gel.
In another form the invention could be said to reside in a recombinant clone including a replicon and a DNA sequence encoding an altered pneumolysin, said altered pneumolysin being non-toxic and being capable of eliciting an immune response in an animal susceptible to wild-type pneumolysin.
In yet another form the invention could be said to reside in a method of producing an altered pneumolysin including the steps of purifying said altered pneumolysin from an expression system including a recombinant clone with DNA encoding an altered pneumolysin said pneumolysin being substantially non-toxic and being capable of eliciting an immune response in an animal susceptible to wild-type pneumolysin.
Preferably the expression system is a cult
Andrew Peter William
Boulnois Graham John
Hansman David John
Mitchell Timothy John
Paton James Cleland
Hines Ja-Na A.
Young & Thompson
LandOfFree
Pneumolysin mutants and pneumococcal vaccines made therefrom does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Pneumolysin mutants and pneumococcal vaccines made therefrom, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pneumolysin mutants and pneumococcal vaccines made therefrom will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3195039